Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

NCT02579811 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Cancer

Interventions

DRUG: Axitinib

Sponsor

Case Comprehensive Cancer Center